Mr. David Wolf reports

HAMILTON THORNE APPOINTS DR. EKATERINA (KATE) TORCHILIN AS PRESIDENT AND CEO

Hamilton Thorne Ltd. has appointed Dr. Ekaterina (Kate) Torchilin as its new president and chief executive officer, effective Jan. 15, 2024.

Dr. Torchilin is succeeding David Wolf, who is retiring as president and CEO. Mr. Wolf will continue to serve the company as executive chairman. Dr. Torchilin will also join the Hamilton Thorne board of directors upon assuming the CEO role.

Dr. Torchilin is currently the president of the biologicals and chemicals division at Thermo Fisher Scientific, where is she is responsible for the development, manufacture and global commercialization of the cell culture, cell therapy and chemical business that supports the manufacturing of vaccines and biologics therapies. Dr. Torchilin began her career at Thermo Fisher supporting strategic mergers and acquisitions in its life sciences group, and has successfully progressed through a series of operational and general management roles at continually larger businesses, including serving as vice-president and general manager of its purification and pharma analytics business, and vice-president and general manager of its cell culture and cell therapy business. Dr. Torchilin also has over 20 years of experience in the life sciences and health care industries, including serving as global head of connected health and women's health at Alere Inc., where she was responsible for its global business in diagnostic testing supporting healthy pregnancy.

Dr. Torchilin earned a PhD in biochemistry from Tufts University and an MBA from Harvard Business School.

David Wolf, Hamilton Thorne chairman, said: "We are delighted to welcome Kate as our new chief executive at this exciting time in our company's development. Kate's unique combination of exceptional strategic capabilities, proven success at scaling businesses and strong scientific background, will allow her to accelerate innovation and lead the company through our next phase of growth and expansion. The board looks forward to Kate realizing the full potential of Hamilton Thorne as a leader in the global fertility market, and delivering long-term growth and value for all its stakeholders."

Dr. Torchilin added: "I am honoured to have been appointed to lead Hamilton Thorne through its next chapter of growth. It is a business with a strong record of innovation in the fertility space, an impressive global footprint, a strong product and brand portfolio, and a talented and dedicated team. I look forward to working with the team to build on this legacy to further accelerate growth, business performance, and support to our customers and their patients with best-in-class products and services."

As executive chairman, Mr. Wolf will provide leadership and management to the company's board of directors and support Dr. Torchilin in her transition. He will also continue to work actively to develop acquisition initiatives, and strategic stakeholder and industry relationships.

About Hamilton Thorne Ltd.

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in assisted reproductive technologies (ART), research and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, Gynetics and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne's customer base consists of fertility clinics, university research centres, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

We seek Safe Harbor.